Climb Bio presented new nonhuman primate data for CLYM116, a next-generation anti-APRIL monoclonal antibody designed for IgA nephropathy (IgAN). The preclinical study demonstrated a longer half-life and deeper, sustained IgA reductions compared to first-generation therapies. Differentiated pharmacokinetic and pharmacodynamic profiles suggest potential for less frequent dosing and enhanced clinical activity. A Phase 1 trial is slated for initiation in Q4 2025, with biomarker and dosing data expected mid-2026. The latest KDIGO clinical guidelines highlight the need for more active management of IgAN, expanding market opportunities for CLYM116.